# Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

> **NCT07544225** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 6 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Sjogren's Disease With Dry Eyes
- Systemic Sclerosis (SSc)
- Idiopathic Inflammatory Myositis (IIM)

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT07544225
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2043-02-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07544225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07544225, "Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07544225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*